Investors & Media

Investors & Media

About Aptinyx

Aptinyx Inc. is a clinical-stage biopharmaceutical company discovering and developing transformative therapies for challenging disorders of the brain and nervous system. Aptinyx has a proven platform for discovery of novel compounds that work through a unique mechanism to modulate—rather than block or over-activate—NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company currently has three product candidates in clinical development. NYX-2925 is in Phase 2 clinical development as a non-opioid therapy for chronic pain with fast-track designation in painful diabetic peripheral neuropathy (DPN), NYX-783 is in Phase 2 clinical development with fast-track designation for the treatment of post-traumatic stress disorder (PTSD), and NYX-458 is in Phase 2 clinical development for the treatment of cognitive impairment in Parkinson’s disease. Aptinyx is also advancing additional compounds from its proprietary chemistry platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders.

Learn more about Aptinyx »

Stock Information

Change (%) 0


Copyright West LLC. Minimum 15 minutes delayed.

Print Page RSS Email Alerts Investor Contacts